Multidisciplinary care improves amputation-free survival in patients with chronic critical limb ischemia  by Chung, Jayer et al.
From the Society for Clinical Vascular SurgeryFrom
T
Auth
Pres
V
Add
Rep
Su
sio
75
The
to
m
0741
Cop
http
162Multidisciplinary care improves amputation-free
survival in patients with chronic critical limb
ischemia
Jayer Chung, MD, J. Gregory Modrall, MD, Chul Ahn, PhD, Lawrence A. Lavery, DPM, and
R. James Valentine, MD, Dallas, Tex
Background: This study was conducted to quantify the effect of multidisciplinary care (MDC) on amputation-free survival
(AFS) and wound healing within a chronic critical limb ischemia (CLI) population.
Methods: We performed a retrospective, single-center cohort study of consecutive CLI patients presenting to the Vascular
Surgery Service. Patients who received initial and follow-up wound care from the MDC were compared with patients who
received standard wound care (SWC). The MDC team consisted of vascular, plastic, and podiatric surgeons who jointly
managed wound care and directed any other consults or services as deemed necessary. SWC consisted of an inconsistent mix
of providers without a deﬁned manager, including nurses, wound care midlevel providers, general surgeons, internists, or the
patients themselves. The referring physician determined the allocation of patients. The primary outcome variable was AFS,
with a secondary evaluation of wound healing. The effects of baseline demographics, comorbid medical conditions, laboratory
values, ischemic lesion severity and location, Rutherford classiﬁcation, and participation in MDC were assessed. Signiﬁcant
univariate predictors (P < .10) of AFS were entered into a multivariate Cox regression model and assessed at an a [ .05.
Results: Between August 2010 and June 2012, 146 CLI patients (91 male [63%]) were evaluated by the Vascular Surgery
Service and were followed up for a median of 539 days (interquartile range 314-679 days). Ischemic tissue loss was
present in 85 patients (38 at Rutherford category 5, and 47 at Rutherford category 6). Within this cohort, 51 (60%) had
MDC, and 34 (40%) had SWC. Fifty-eight patients (68%) underwent revascularization (open in 17, endovascular in 35,
and hybrid in 6), 14 (8%) were managed with primary major amputation, and 13 (15%) declined revascularization. AFS
was superior for patients in the MDC arm vs the SWC arm (593.3 6 53.5 days vs 281.0 6 38.2 days; log-rank, P[ .02).
Wound-healing times favored the MDC arm over the SWC arm (444.56 33.2 days vs 625.26 126.5 days), although this
was not statistically signiﬁcant (log-rank, P[ .74). Multivariate modelling revealed that independent predictors of major
amputation or death, or both, were nonrevascularized patients (hazard ratio [HR], 3.76; 95% conﬁdence interval [CI],
1.78-8.02; c2, P < .01), treatment by SWC (HR, 2.664; 95% CI, 1.23-5.77; c2, P[ .012), and baseline nonambulatory
status (HR, 1.89; 95% CI, 1.17-2.85; c2, P < .01).
Conclusions: MDC pathways for the management of a population of CLI patients improved AFS by greater than twofold
and should be the standard of care for the CLI population. Baseline nonambulatory status and unrevascularized patients
also predict worse AFS. Wound healing remains prolonged regardless of preoperative or postoperative wound care.
Future study is required to evaluate the costs and functional outcomes for MDC in the management of CLI. (J Vasc Surg
2015;61:162-9.)Suboptimal outcomes after revascularization in chronic
critical limb ischemia (CLI) persist despite the dramatic ex-
plosion of novel techniques, therapies, and devices. Infrain-
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://dx.doi.org/10.1016/j.jvs.2014.05.101is the current gold standard, but 25% of patients fail to survive
with an intact limb at 1 year.1 Endovascular therapies fare
similarly, with primary patency of w34% and amputation-
free survival (AFS) up to 75%.2 Because of the modest results
after revascularization, multiple researchers have sought other
adjunctive therapies that may improve AFS in CLI.
Several consensus documents have recently been
released advocating for the institution of multidisciplinary
care (MDC) teams to improve outcomes in CLI.3,4 The
guidelines are timely, due to the incipient epidemic of
CLI and to the increasing prevalence of atherosclerotic
risk factors, especially diabetes, obesity, and advanced age
(>65 years).5 The vital core of a limb-salvage team consists
of a vascular surgeon and a podiatric surgeon.3,4 The prem-
ise is that early restoration of nutritive blood ﬂow and
wound care will most strongly predict wound healing and
limb salvage. More extensive teams consist of the same
core in conjunction with members of plastic, orthopedic,
and general surgery, along with cardiology and infectious
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because prior studies have showed improved outcomes
with improved atherosclerotic risk factor management6
and combined specialty surgical approaches to preserve
limb length.7 Unfortunately, comparative-effectiveness
research to date is insufﬁcient to deﬁne the optimal multi-
disciplinary podiatry-based team.
Opponents of MDC teams point to the fact that the
partial foot amputations performed by podiatrists may
only temporarily decrease major amputation rates due to
the conversion rate of >30% of partial foot amputations
into major amputations (above the ankle), with an w50%
nonhealing rate.8,9 Advocates for a more aggressive stance
toward major amputation cite the potential cost beneﬁts
associated with decreasing the number of procedures and
wound care. Owing to the spiraling cost of health care
and the passage of the Affordable Care Act (ACA), this is
particularly germane.10
The purpose of this study was to examine the effect of
MDC on outcomes in CLI. We hypothesized that patients
who underwent MDC for ischemic lower extremity ulcera-
tions would have improved AFS relative to patients who un-
derwent standard wound care (SWC). We therefore sought
to examine the association of MDC amongst covariates
known to predict AFS. Secondarily, we sought to describe
the time to complete wound healing in either group.
METHODS
All consecutive patients presenting with CLI to the
Vascular Surgery Service at Parkland Memorial Hospital
(PMH) in Dallas, Tex, between August 1, 2010, and
June 2012 were prospectively entered into a CLI outcomes
database. Vascular surgeons performed all revasculariza-
tions in the cohort. Contrary to our prior work,6 the anal-
ysis was limited to patients with Rutherford class 5 or 6
disease.11 The date range was selected a priori to ensure
that patients analyzed could have at least 1 year of
follow-up. All CLI patients presenting to the clinic or as
inpatient consultations were included for analysis, irrespec-
tive of whether an intervention was performed. The elec-
tronic medical record was reviewed to conﬁrm each
patient’s data, with vital status conﬁrmed by query of the
Social Security Death Index (http://ssdi.roots.web).
All data were abstracted by a trained data abstractor
(D.T.) or by a single vascular surgeon (J.C.), with the ve-
racity of all data conﬁrmed by a single vascular surgeon
(J.C.). Institutional Review Board approval (#092011-
043) was obtained before any data collection or analysis.
Consent was not obtained as this was not deemed to be
necessary by the Institutional Review Board due to the
minimal risk involved to the patients. The analysis of the ef-
fect of MDC upon outcomes in CLI was prespeciﬁed in the
Institutional Review Board protocol.
Inclusion and exclusion criteria, and demo-
graphics. The diagnosis of CLI was made as deﬁned pre-
viously but consisted of patients with >2 weeks of
symptoms of ischemic rest pain and ulcerations/gangrene
in conjunction with objective evidence of hemodynamicinsufﬁciency.1,11,12 Patients were excluded if they pre-
sented with nonatherosclerotic disease, such as vasculitis or
Buerger’s disease, or had antecedent acute limb ischemia.
Patients with intermittent claudication only or prior major
amputation to the index limb were excluded. Patients with
prior partial foot amputations (digital amputations, ray
amputations, or transmetatarsal amputations [TMAs]) to
the index limb were included. Analysis was limited to those
with ischemic ulcerations because these are the patients
where multidisciplinary wound care is germane.
Our data collection did not capture every CLI patient
that presented to PMH because interventional cardiology
and radiology perform a minority of the procedures. Gen-
eral surgeons do not perform any revascularizations at our
institution, except for trauma. The general and orthopedic
surgeons perform some minor and major amputations in-
dependent of vascular surgical consultation. Procedures
performed without a vascular surgical consultation were
excluded because data were insufﬁcient to determine
whether these patients met the criteria of the diagnosis of
CLI as deﬁned above.1
Demographic data (baseline age, gender, ethnicity, in-
surance status), medical, and prior surgical comorbidities,
medications, and laboratory values were collected, as
described in our prior work, and are described in more
detail in the Supplementary Table (online only).13 All
endovascular (balloon angioplasty, atherectomy, and stent-
ing), open (bypass or endarterectomy), and hybrid (combi-
nation of open and endovascular) procedures were deﬁned
as revascularizations. Above-the-knee amputations (AKAs)
and below-the-knee amputations above the ankle (BKAs)
were deﬁned as major amputations. Minor amputations
were deﬁned as any partial foot amputation that preserved
the ankle joint. Debridement and local wound care were
minor procedures not involving resection of any of the
bony segments of the foot. Locations of wounds were
deﬁned by the most proximal location of a wound on the
foot (digit[s]; metatarsal heads, midfoot, heel, malleoli,
or calf). If multiple wounds were present, the most prox-
imal wound was used to deﬁne the location of the wound,
as described previously.13 Wounds were categorized after
the initial debridement if the patient presented with sepsis.
The size of the initial wounds was not recorded.
Deﬁnition of MDC and SWC arms and allocation.
The groups were deﬁned by the services that were initially
were consulted and performed the initial wound care for
the patients. If patients crossed over into MDC afterwards,
or vice-versa, they were still analyzed by the initial treat-
ment provided. Patients were deﬁned as having undergone
MDC when care was directed in concert by the podiatric,
plastic, and vascular surgeons at PMH. Consults with in-
fectious disease, internal medicine, nutritional services, and
cardiology were directed as needed. Weekly discussions
regarding shared patients were held to determine urgency
of procedures and care plans. The decision to perform any
intervention was performed at the discretion of the
attending physicians, after an assessment of the patient’s
clinical and anatomic features and functional status in
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cular-ﬁrst” approaches were not uniformly undertaken2;
rather, the revascularization that would provide direct ﬂow
to the foot was the preferred modality, ideally angiosome-
directed when anatomically possible.14 Codiﬁcation of the
outpatient wound care plan was also directed jointly be-
tween the podiatric and vascular surgeons, with appropriate
preventative ofﬂoading and tendon-lengthening pro-
cedures performed as needed.
The SWC patients were deﬁned as those in whom the
general surgeons were the initial service to care for the
pedal wounds and bore responsibility for the regimenting
the wound care. Referrals to other care providers were typi-
cally made in series, each of whom evaluated, diagnosed,
and treated the patients with variable degrees of communi-
cation with one another. The general surgeons were
responsible for the partial foot amputations, major amputa-
tions, and subsequent care of the patients. The wound care
was ultimately composed of a heterogeneous mixture of
the general surgeons, wound care nurses, primary care phy-
sicians, midlevel providers, the patients or their family
members, or both.
Allocation into either of the treatment arms was deter-
mined by the initial consulting service. If the initial inpatient
or outpatient referral from the emergency department, hos-
pitalist, or internal medicine service was made to the general
surgery service upon initial presentation, then the podiatric
or plastic services were not involved with subsequent wound
care or partial foot or major amputations. No formal crite-
rion is uniformly used by these services to determine
whom to consult. Subsequent care of wounds was deter-
mined by the service (MDC or SWC) that initially managed
the wounds. All of the vascular surgical care in this cohort
was provided by the Vascular Surgery Service.
Deﬁnition of AFS, complete wound healing, and
the statistical analysis plan. The primary end point was
AFS at last known follow-up. Secondarily, limb salvage
and survival rates were also described to ascertain the main
driver of the combined end point. After grouping the pa-
tients by the treatment strategy (MDC vs SWC), the effect
of baseline demographics, medical comorbidities, and
wound characteristics on actuarial estimated AFS was
evaluated among the population presenting with Ruth-
erford class 5 or 6 lesions.
Causes of death were deﬁned previously6,13 and
described similarly in this report. The subsequent fate of
each foot wound was also described. Complete wound
healing was deﬁned previously13 as the time from initial
consultation to the time where all surgical and ischemic
wounds were completely epithelialized. This deﬁnition
was used because it most accurately described wound heal-
ing from a patient and resource-utilization perspective.
Continuous statistics are presented as a median and
interquartile range (IQR), with frequencies and percent-
ages used for categoric data. Kaplan-Meier and Cox pro-
portional hazards regression models were performed
where appropriate to evaluate AFS, limb salvage, and over-
all survival. Hazard ratios (HRs) are presented with 95%conﬁdence intervals (CIs). Each variable was individually
evaluated in a univariate Cox regression model evaluating
AFS, with candidate covariates for modelling selected
based on a P < .25. These candidate covariates were
then used to construct a multivariate model. Forward selec-
tion was used, with criterion for entry being an a ¼ .10,
with the statistical signiﬁcance was assessed at an a ¼
.05. Survival estimates are presented as a mean 6 standard
error. Data were analyzed with SAS 9.3 software (SAS
Institute Inc, Cary, NC).
RESULTS
Demographics. During the study period, 146 patients
presented with CLI, 85 of whom had Rutherford class
5 (n ¼ 38) or 6 (n ¼ 47) ischemia. These 85
patients comprised the study cohort. Fifty-four patients
(63.5%) were male, and the median age was 59 years
(IQR 52-63 years). Fifty-one patients (60.0%) underwent
MDC, and 34 (40.0%) underwent SWC. There was a high
prevalence of hypertension and diabetes (Table I).
Approximately half of the wounds were located at the
digital level at baseline (n ¼ 43; Table II).
Treatment strategy, AFS, and secondary out-
comes. Revascularization was performed in 58 patients
(open in 17, endovascular in 35, and hybrid in 6). There
were 14 primary amputations (six AKAs and eight
BKAs). Thirteen patients refused the recommended ther-
apy because of patient noncompliance (n ¼ 8) or because
of medical comorbidities precluding timely surgery eventu-
ally leading to loss to follow-up (n ¼ 5). At the last known
follow-up, 39 patients met the primary end point, with
nine deaths, and 30 surviving after a major amputation (20
AKAs and 10 BKAs). Wounds failed to heal in 24 patients
(28%) at the last follow-up. The median follow-up for the
study cohort was 539 days (IQR, 314-679 days). The
estimated mean AFS for the entire cohort was 508 6
42 days (1.39 6 0.11 years).
Among the patients who were revascularized, the esti-
mated mean AFS, limb salvage, and overall survival were
579 6 50, 914 6 83, and 257 6 5 days, respectively.
No statistically signiﬁcant differences in AFS (log-rank,
P ¼ .94), limb salvage (log-rank, P ¼ .36), or overall sur-
vival (log-rank, P ¼ .43) were observed between the open,
endovascular, and hybrid revascularization strategies. The
estimated mean wound-healing time was 555.1 6
59.6 days (1.52 6 0.16 years) for the entire cohort.
MDC vs SWC. More patients ambulated indepen-
dently in the MDC group vs the SWC group (73% vs
47%, respectively; c2, P ¼ .01). The MDC group also had
a signiﬁcantly higher median ankle-brachial index (0.65;
IQR, 0.40-1.06) compared with the SWC group (0.41;
IQR, 0.35-0.59; Mann-Whitney U, P ¼ .03), and also had
a signiﬁcantly higher proportion of patients with incom-
pressible ankle-brachial indexes (c2, P ¼ .08) and a
higher proportion of patients with end-stage renal disease
(c2, P ¼ .45). The median HbA1c was 7.45 (IQR 6.55-
10.0) in the MDC group and 7.3 (IQR, 6.0-9.1) in the
SWC arm (Mann-Whitney U, P ¼ .61). No differences
Table I. Patient baseline demographics and vascular history
Variablesa
Wound care group
PMDC (n ¼ 51) SWC (n ¼ 34)
Age, years 59 (51, 62) 60 (55, 68) .30
Gender (% male) 32 (63) 22 (65) .47
Medical comorbidities
Coronary artery disease 15 (29) 9 (26) .52
History of
Coronary artery bypass 6 (12) 2 (6) .46
Percutaneous coronary intervention 6 (12) 5 (15) .86
Myocardial infarction 11 (22) 5 (15) .29
Stroke 2 (4) 3 (9) .43
Chronic pulmonary obstructive disease 3 (6) 5 (15) .36
Congestive heart failure 6 (12) 5 (15) .86
Diabetes mellitus 41 (80) 28 (82) .36
Hypertension 40 (78) 29 (85) .71
Hypercholesterolemia 25 (49) 12 (35) .12
Dialysis-dependent renal failure 6 (12) 2 (6) .46
Tobacco abuse 33 (65) 23 (68) .84
Current tobacco abuse 19 (37) 15 (44) .58
Baseline laboratory values
Hemoglobin A1c, % 7.45 (6.55-10.0) 7.30 (6.0-9.1) .61
Hemoglobin, g/dL 11.2 (10.2-13.0) 11.8 (10.4-13.7) .11
White blood cell count, 103 9.0 (6.5-11.5) 9.0 (6.2-11.7) .92
Serum creatinine, mg/dL 0.90 (1.21-0.78) 0.91 (0.75-1.08) .43
Baseline medications
Statin 26 (51) 19 (56) .87
Antiplatelet 30 (59) 17 (50) .16
b-blocker 22 (43) 13 (38) .36
ACE-I/ARB 25 (49) 17 (50) .64
Insulin 24 (47) 13 (38) .19
Vascular history
Prior revascularization in the index limb 10 (20) 9 (26) .42
Rutherford class 5 (minor tissue loss) 23 (45) 15 (44) .97
Rutherford class 6 (severe tissue loss) 28 (55) 19 (56) .98
Independently ambulatory 37 (73) 16 (47) .01b
Ankle-brachial index 0.65 (0.40-1.06) 0.41 (0.35-0.59) .03b
Incompressible ankle-brachial index 12 (23.5) 3 (8.8) .08b
Septic wounds at presentation 20 (39) 11 (32) .66
ACE-I, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MDC, multidisciplinary care; SWC, standard wound care.
aContinuous data are presented as mean (interquartile range) and categoric data as number (%).
bStatistically signiﬁcant.
Table II. Distribution of the location of the most
proximal wound between the multidisciplinary care
(MDC) and standard wound care (SWC) groups, after
debridement for wet gangrene
Location of the most
proximal ischemic wound
Wound care group, No. (%)
MDC (n ¼ 51) SWC (n ¼ 34)
Digital only 26 (51) 17 (50)
Metatarsal head 5 (10) 4 (12)
Midfoot 7 (14) 3 (9)
Ankle 9 (18) 4 (12)
Calf 4 (7) 6 (17)
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sentation between the MDC and SWC groups (Table II).
The 1-year Kaplan-Meier estimated AFS was statisti-
cally signiﬁcantly superior in the MDC cohort vs the
SWC cohort (67% 6 0.07% vs 42% 6 0.08%; log-rank,
P ¼ .02). Similarly, the 2-year AFS was superior in the
MDC vs the SWC cohort (64% 6 0.07% vs 35.4% 6
0.08%; log-rank, P ¼ .02; Fig). There was no statistically
signiﬁcant difference in overall survival between the two
groups (log-rank, P ¼ .37); however, the mean estimated
limb salvage was statistically signiﬁcantly superior in the
MDC vs the SWC group (871.1 6 105.1 days vs
515.4 6 115.8 days, respectively; log-rank, P < .01).
Mean wound-healing times favored the MDC group vs
the SWC group (426.1 6 31.1 days vs 610 6
91.0 days), although this did not reach statistical signiﬁ-
cance (log-rank, P ¼ .55).
Within the subgroup that underwent revasculariza-
tion, the estimated mean AFS was longer in the MDCgroup (n ¼ 34) compared with the SWC arm (n ¼ 2;
597.8 6 61.6 days vs 272.4 6 33.8 days), although this
was not statistically signiﬁcant (log-rank, P ¼ .69). The
estimated wound healing time was shorter in the MDC
Table III. Management of the presenting necrosis
between the multidisciplinary (MDC) and standard
wound care (SWC) groups, including patients who did
not undergo a primary major amputation and were
willing to undergo care
Management of tissue loss
Wound care, No. (%)
MDC (n ¼ 34) SWC (n ¼ 24)
Debridement and local
wound care
16 (47) 10 (42)
Digital amputation(s) only 7 (20) 8 (33)
TMA 11 (32) 6 (25)
TMA, Transmetatarsal amputation.
Fig. Kaplan-Meier analysis compares patients presenting with ischemic tissue loss and treated with multidisciplinary
care (MDC) vs standard wound care (SWC). The standard error (SE) exceeds 10% at 848 days.
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126.5 days) although this was also nonstatistically signiﬁ-
cant (log-rank, P ¼ .74). More patients underwent a
TMA in the MDC arm than in the SWC arm (32% vs
25%), although this was not statistically signiﬁcant
(c2, P ¼ .58; Table III).
At last follow up, there were six major amputations
(17%) in the MDC arm, all AKAs. Four occurred after
failed TMAs and two after failure of local wound therapy.
Eight major amputations (32%; three BKAs and ﬁve
AKAs) occurred in the SWC group. Three failures occurred
after wound care only (three AKAs), with three more fail-
ures occurring after digital amputations (two BKAs and
one AKA). Two more failures occurred after TMAs in
the SWC arm (one BKA and one AKA).
Univariate and multivariate comparison. On univar-
iate Cox regression analysis (P < .10), variables that
predicted major amputation or death, or both, at last
follow-up included baseline nonambulatory status (HR,
2.01; 95% CI, 1.50-2.69; c2, P < .01), serum creatinine
(HR, 1.15; 95% CI, 0.99-1.34; c2, P ¼ .07), treatment
in the SWC cohort (HR, 2.14; 95% CI, 1.14-4.04; c2,
P ¼ .02), and nonrevascularized patients (HR, 2.38; 95%
CI, 1.26-4.50; c2, P < .01). Increased hemoglobin was
protective on univariate analysis (HR, 0.818; 95% CI,
0.69-0.97; c2, P ¼ .02), as was an absence of end-stage
renal disease (HR, 0.41; 95% CI, 0.17-0.97; c2, P ¼ .04;
Table IV). Multivariate Cox regression analysis revealed
that independent predictors of major amputation or death,
or both, were baseline nonambulatory status (HR, 1.89;95% CI, 1.17-2.85; c2, P ¼ .01), treatment in the SWC
cohort (HR, 2.66; 95% CI, 1.23-5.77; c2, P < .01), and
nonrevascularization (HR, 3.76; 95% CI, 1.78-8.02; c2,
P < .01; Table V).DISCUSSION
Treatment with MDC resulted in a durable twofold in-
crease in AFS, comparable with the effect of revasculariza-
tion and baseline ambulatory status. The difference is
driven predominantly by improvements in limb salvage in
the MDC cohort, with conversion to major amputation
occurring at twice the rate in the SWC arm. Wound healing
favors the MDC arm overall, although complete healing
Table IV. Univariate Cox regression analysis describing
the risk of major amputation or death, or both, at last
known follow-up
Variable
Unadjusted
HR (95% CI) P
Age 1.02 (0.99-1.06) .11
Gender 1.21 (0.76-1.95) .51
Medical comorbidities
No history of coronary artery
disease
0.91 (0.45-1.84) .80
History of coronary artery bypass 2.34 (0.56-9.73) .18
No prior percutaneous
coronary intervention
0.79 (0.33-1.89) .59
No chronic pulmonary
obstructive disease
0.64 (0.35-1.71) .19
No congestive heart failure 0.67 (0.31-1.45) .31
Nondiabetic 0.65 (0.27-1.56) .33
No history of myocardial
infarction
0.82 (0.38-1.79) .61
Nonhypertensive 0.54 (0.21-1.39) .20
Hypercholesterolemia 1.12 (0.59-2.13) .14
History of stroke 1.13 (0.31-5.40) .72
No dialysis-dependent renal failure 0.41 (0.17-0.97) .04a
Tobacco abuse 1.64 (0.75-3.6) .22
Baseline laboratory values
Hemoglobin A1c, % 1.12 (0.95-1.65) .17
Hemoglobin, g/dL 0.82 (0.69-0.97) .02a
White blood cell count, 103 1.06 (0.99-1.13) .11
Serum creatinine, mg/dL 1.15 (0.99-1.34) .07a
Baseline medications
Statin 1.16 (0.47-2.86) .75
Antiplatelet 1.17 (0.62-2.21) .62
b-blocker 1.12 (0.60-2.13) .71
ACE-I/ARB 0.96 (0.90-1.80) .90
Insulin 1.44 (0.69-3.0) .96
Vascular history
Prior revascularization in
the index limb
1.37 (0.74-2.54) .31
Rutherford classiﬁcation 1.41 (0.74-2.66) .29
Nonambulatory status 2.01 (1.5-2.69) <.01a
Ankle-brachial index 1.06 (0.45-2.50) .90
Septic wounds at presentation 1.51 (0.72-3.18) .28
Initial wound location 3.01 (0.58-15.51) .19
SWC 2.14 (1.14-4.04) .02a
Managed without revascularization 2.24 (1.18-4.25) <.01a
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CI, conﬁdence interval; HR, hazard ratio; SWC, standard
wound care.
aStatistically signiﬁcant.
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with 46% of patients ultimately reaching the end point of
major amputation or death, or both, at last follow-up. Pop-
ulation-based efforts to improve limb salvage in the CLI
population should implement multidisciplinary strategies
in conjunction with ongoing efforts to improve the ability
to revascularize ambulatory patients with CLI.
Comparative effectiveness research is sparse in CLI.
Our data help to bridge a gap in knowledge regarding
the role of MDC6 by extending similar results found by
other investigators.15-18 Prior investigators had studied
the effect of MDC teams on diabetic populations, with
limited modelling performed to quantify the magnitude
of the effect of MDC. Our study provides data thatquantify the magnitude of the effect of MDC on AFS,
which was comparable to the effects of ambulatory status
in our cohort.
Prior works also suffered from limited follow-up; hence,
the improved AFS observed by other studies may have been
due to a failure to capture the rate of conversion to major
amputation after partial foot amputations. Our cohort has
a longer duration of follow-up that enables our group to
capture patients who were converted to major amputations.
Our data conﬁrm the guidelines from multiple profes-
sional organizations.3 Intuitively, our results make sense,
because the patients treated in the SWC arm suffer from
disjointed evaluations, with variable communication be-
tween providers resulting in heterogeneous and sometimes
conﬂicting evaluations and recommendations.
In contrast, the MDC arm results in a more coordi-
nated delivery model. The advantages of the MDC
approach are particularly apparent in the CLI population,
which is notoriously difﬁcult to monitor due to nonadher-
ence to medical recommendations and follow-up.6 The
MDC model improves access to care, because multiple
team members can see the patients. Our MDC model is
less elaborate than some centers because it consists mainly
of members of the vascular, podiatric, and plastic surgery
specialties. Further study will be required to clarify how
to standardize MDC in CLI.
The most novel ﬁnding is durability of the improved
AFS in the MDC arm. The data refute the notion that par-
tial foot amputations will fail to heal and ultimately result in
a major amputation or nonhealing in 30% to 50% of pa-
tients.8,18 The improvements in limb salvage in the MDC
cohort likely stem from improved operative selection, tech-
nical performance of the partial foot amputation, and post-
amputation wound care, stemming from the superior
expertise with partial foot amputations, wound care, and
off-loading that the podiatric surgeons garner relative to
their peers in vascular or general surgery.3 Moreover, podi-
atric surgeons use tendon-lengthening procedures19 that
are outside of the scope of most general and vascular sur-
geons, which may also contribute to improved outcomes.
The improved access to care also improves the ability to
survey and potentially intervene before the development
of irrevocable necrosis in the foot.20 Finally, the improved
surveillance may help to ensure that revascularization ef-
forts are fully maximized, thereby improving AFS. Further
cost-analyses21 and analyses of functional outcomes22 will
further understanding of the comparative-effectiveness of
MDC compared with the SWC and is required to deter-
mine how elaborate MDC needs to be.
Our data are generalizable to a broader population
of CLI, not only the subsegment that is revascularized.
This lack of indication bias23 permits a more accurate
quantiﬁcation of bioeffects, such as beneﬁcial effect of
revascularization in CLI, in our CLI population. Years of
research have made it clear that revascularization improves
outcomes in CLI; however, the magnitude of the effect
has been recently debated, as shown by an observational
study of CLI patients who could not undergo vascular
Table V. Multivariate Cox regression analysis describing the independent predictors of major amputation or death, or
both, at last known follow-up
Variable Unadjusted HR (95% CI) P Adjusted HR (95% CI) P
Initial nonambulatory status 2.01 (1.50-2.69) <.01 1.89 (1.17-2.85) .01a
Baseline serum creatinine, mg/dL 1.15 (0.99-1.34) .07
Baseline serum hemoglobin, mg/dL 0.818 (0.69-0.97) .02
No dialysis dependence 0.41 (0.17-0.97) .04
SWC 2.14 (1.14-4.04) .02 2.66 (1.23-5.77) .01a
No revascularization 2.38 (1.26-4.50) <.01 3.76 (1.78-8.02) <.01a
CI, Conﬁdence interval; HR, hazard ratio; SWC, standard wound care.
aStatistically signiﬁcant.
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mains the single most signiﬁcant factor independently pre-
dicting major amputation or death, or both, in CLI by
greater than a factor of three. These data are signiﬁcant
when considering trial design in CLI because our data
benchmark the magnitude of beneﬁt of revascularization
relative to unrevascularized patients.
Finally, our data are also signiﬁcant when attempting to
stratify patients between individual practitioners, institu-
tions, and clinical trials. The passage of the ACA has
resulted in the creation of Accountable Care Organizations
designed to attempt to align Medicare reimbursement with
the quality of care provided.10 Because the quality of
wound care signiﬁcantly affects outcomes, perhaps the in-
clusion of the variables that capture whether patients
received MDC when assessing outcomes will better enable
equitable comparisons and compensation.
Wound-healing outcomes vary widely in the literature,
with complete wound healing achieved in 40% to 50% of
patients between 6 and 10 months.13,25 Our results are
worse than those of infrainguinal bypass alone, the current
gold standard of therapy, likely because of selection bias.
Comparisons are difﬁcult because prior trials had highly
variable wound care8,13,15-17 and deﬁnitions of wound
healing. Moreover, stratiﬁcation by other factors known
to inﬂuence wound healing, such as baseline wound size
and nutritional status,26 has not been routine. Future study
would beneﬁt from evaluation of baseline wound size and
nutritional parameters while controlling for other known
covariates of wound healing and also AFS, limb salvage,
and overall survival.
Although our data demonstrate the independent asso-
ciation between MDC and AFS in CLI, a number of limi-
tations must be acknowledged. Our cohort remains a
relatively small single-center cohort drawn from the
inner-city population of Dallas, Tex. This precluded our
ability to perform a propensity score analysis. This would
have been ideal to mitigate selection bias, which is likely
present in our cohort due to the referral tendencies of
the physicians seeking limb-salvage expertise. Further pro-
spective study from larger, multi-institutional CLI popula-
tions will be required to conﬁrm our ﬁndings. This is
particularly vital to further clarify the role of diabetes (insu-
lin-dependent vs noninsulin dependent) and the role of
glycemic control on AFS.Moreover, the study is observational, with no labora-
tory evaluations, imaging, or procedures performed outside
of those deemed necessary by the physicians caring for the
patient; hence, data are missing for some of the covariates.
The prospective data collection mitigated this effect relative
to other studies. Cost-analyses were not performed and
warrant future study, especially in light of passage of the
ACA. Future study will be required to ascertain the optimal
members of the multidisciplinary team and their roles to
optimize MDC of CLI patients.
CONCLUSIONS
MDC improves AFS by greater than a factor of two,
rivaling the bioeffect of baseline ambulatory status. MDC
represents a coordinated process of care that should
become the standard of care. Future trials and quality as-
sessments could beneﬁt by stratifying patients by the qual-
ity of wound care that patients receive (MDC vs SWC).
Further research will help to clarify the optimal compo-
nents of MDC, cost, and functional outcomes.
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Supplementary Table (online only). Data dictionary for the patient demographics, baseline medical comorbidities, and
vascular surgical history used for analysis. This is the same data dictionary used in our prior work.6
Variable Deﬁnition
Gender Male or female
Age at diagnosis years
Rutherford classiﬁcation of index limb 4, 5 or 6
Initial ambulatory status Independent, with an assist device, nonambulatory
Initial living status Independent/community assisted/nursing home
Diabetes Yes or no
Tobacco use Current, former, or never smoker
Hypercholesterolemia Yes or no
Hypertension Yes or no
Coronary artery disease Yes or no
History of myocardial infarction Yes or no
History of a coronary artery bypass Yes or no
History of a percutaneous coronary intervention Yes or no
History of stroke Yes or no
Congestive heart failure Yes or no
Chronic obstructive pulmonary disease Yes or no
End-stage renal disease Yes or no
History of a hypercoagulable state Yes or no
History of a prior lower extremity bypass Yes or no
History of prior lower extremity stenting Yes or no
Baseline laboratory values
White blood cell count 103 cells/mL
Hemoglobin g/dL
Creatinine mg/dL
Serum albumin mg/dL
Hemoglobin A1c %
Ankle-brachial index of the index limb Ratio of the highest systolic pressures in either brachium and index ankle
Location of the most proximal wound Digital, metatarsal head, midfoot, heel, ankle, calf
Severity of sepsis at presentation Ulcer, dry gangrene, wet gangrene
Statin Yes or no
ACE-I/ARB Yes or no
Antiplatelet therapy Yes or no
b-blocker Yes or no
Insulin Yes or no
Baseline vitals, height and weight Numeric
Revascularization Yes or no
Endovascular Balloon angioplasty, stent, atherectomy
Open surgical Bypass or endarterectomy
Hybrid Combination of endovascular and open
Date of initial vascular consultation Date
Date of surgery Date
Consulting service Text
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin receptor blocker.
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